Closing
Do SGLT2 inhibitors improve inflammation & biomarkers more than other treatments?
Mostly studied in type 2 & unspecified diabetes. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Individual and Combined Endothelin Receptor and SGLT2 Antagonism in Adults With Type 1 Diabetes Mellitus and Chronic Kidney Disease: a Phase 2, Multicenter,…NCT06072326 · not yet recruiting · started 2026
- Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant RecipientsNCT06625073 · recruiting · started 2026
- The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKDNCT07060417 · not yet recruiting · started 2026
- Role of Finerenone in African American Veterans With Diabetic Kidney DiseaseNCT07155694 · not yet recruiting · started 2026
- Sodium-Glucose Cotransporter-2 Inhibitor for Amelioration of Acute Cardiorenal Syndrome: A Randomized Controlled TrialNCT07273838 · recruiting · started 2026
The evidence so far
- Registered trials
- 175
- With posted results
- 25
- Published papers
- 3
Of 6 decided analyses: 2 favor sglt2 inhibitors, 2 find no difference, 2 favor the comparator.
Papers
- Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.Trial report · 2022
- Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.Meta-analysis / systematic review · 2025
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.Trial report · 2018
Trials
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive MedicationNCT01195662 · 1 posted result
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)NCT01137474 · 1 posted result
- DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients.NCT03338855 · 1 posted result
- Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT02564926 · 1 posted result
- Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class IIINCT03968224 · 2 posted results
- Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney DiseaseNCT05719714
- SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)NCT05037695
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409